DISCLOSURE GUIDE - CAP Annual Meeting...Disclosure Guide cap19 4 Credit(s) .Physicians should only claim credit commensurate with the extent of their participation in the activity

DISCLOSURE GUIDE Gaylord Palms Resort September 21-25, 2019 Orlando, Florida

cap19 Disclosure Guide

1

The College of American Pathologists (CAP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. All authors/speakers/planners/ reviewers of a CAP educational activity must disclose to the program audience any financial interest or relationship with any proprietary entity producing, marketing, reselling or distributing health care goods or services consumed by, or used on patients that may be discussed in the educational activity or with any proprietary entity producing, marketing, reselling or distributing health care goods or services consumed by, or used on patients that is directly competitive with a product discussed in the presentation. Relevant financial relationships are considered to be any financial relationships in any amount occurring within the past 12 months that create a conflict of interest. The College of American Pathologists does not view the existence of these interests or uses as implying bias or decreasing the value to participants. The CAP, along with the Accreditation Council for Continuing Medical Education (ACCME), feels that this disclosure is important for the participants to form their own judgment about each presentation. Below you will find the financial disclosure relationships for anyone who was able to affect content of this educational activity. The CAP does identify and manage all potential conflicts of interest to ensure that all educational activities promote improvements or quality in healthcare and are free of commercial bias for or against a product/service.

CAP19 COURSE PLANNERS

The following planners have no financial relationships to disclose:

• Sarah Muntzing Bean, MD, FCAP

• Kyle T. Bradley, MD, MS, FCAP

• Gregory G. Davis, MD, FCAP

• Donna E. Hansel, MD, PhD, FCAP

• John Michael Kennedy, MD, BA

• Christina S. Kong, MD, FCAP

• Gordon L. Love, MD, FCAP

• Kisha Mitchell Richards, MD, FCAP

• David L. Slater, MD, FCAP

• Laura Justine Tafe, MD, FCAP

• Lynne Uhl, MD, FCAP

• Kim Kruger, MBA, MT(ASCP)

• Lorretta Morrison, MS The following planners have these financial relationships to disclose:

• Bruce A. Beckwith, MD, FCAP: Gestalt Diagnostics, advisory board member beginning Jan 2019, consulting fee

• David C. Hoak, MD, FCAP: Gestalt Diagnostics, medical director and board member, stock option

• Robert M. Najarian, MD, FCAP: Medtronic, consultant, compensation

• Jessica Poisson, MD, FCAP: Cerus, research, research funds

• John C. Spinosa, MD, PhD, FCAP: Lexent Bio, co-founder and chief medical information officer, equity and salary

Disclosure Guide cap19

2

SELF-ASSESSMENT MODULE (SAM) COURSE PLANNERS

Self-Assessment Module (SAM) courses meet the American Board of Pathology's Maintenance of Certification (MOC) requirements. Participants who successfully complete an online assessment, available after the session, may apply their earned credit(s) to the American Board of Pathology’s ABP Self-Assessment Module (SAM) requirements. The following CAP19 courses are SAM-eligible:

• A1996S

• H1615S

• H1943S

• M1710S

• M1741S

• M1821S

• M1824S

• M1872S

• M1876S

• M1944S

• M1971S

• S1706S

• S1725S

• S1727S

• S1729S

• S1739S

• S1748S • S1792S

• S1823S

• S1828S

• S1836S

• S1842S

• S1851S

• S1854S

• S1857S

• S1858S

• S1860S

• S1864S

• S1868S

• S1869S

• S1870S

• S1877S

• S1884S

• S1917S

• S1922S

• S1924S

• S1926S

• S1953S

• S1959S

• S1963S

• S1967S The following SAM planners have no financial relationships to disclose:

• Susan Fore

• Sebastin Francis

• Trish Glover

• Kelly Hayes

• Abby Thomsen


3

A1996S Focus on GU Pathology: Advanced Answers for Daily Practice

Mahul B. Amin, MD, FCAP has the following relevant financial relationships to report: Core Diagnostics, advisory board, stock; Cell Max, advisory board, stock option; Precipio, advisory board, stock option; Advanced Clinical, consultant, consulting fee; Urogen, central case reviewer, case review fee.

John C. Cheville, MD has no relevant financial relationships to report.

Donna E. Hansel, MD, PhD, FCAP (Moderator) has no relevant financial relationships to report.

Peter A. Humphrey, MD, PhD, FCAP has no relevant financial relationships to report.

Anil Parwani, MD, PhD, MBA, FCAP has no relevant financial relationships to report.

Debra L. Zynger, MD, MS, FCAP has no relevant financial relationships to report.

Learning Objectives:

• Diagnose carcinomas of the genitourinary tract including its variants.

• Recognize benign mimickers and avoid misdiagnosis that could lead to unnecessary treatment.

• Address staging challenges and how to successfully approach these in grossing and microscopy.

No In-Kind or Commercial Support has been received for this activity.

CME Category 1: The CAP designates this live educational activity for a maximum of 6.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

A1997C CAP Inspector Training Seminar

Bharati S. Jhaveri, MD, FCAP has no relevant financial relationships to report.

Bradley S. Karon, MD, PhD, FCAP has the following relevant financial relationships to report: Roche Diagnostics, consultant, consulting fee.

Deborah A. Perry, MD, FCAP has no relevant financial relationships to report.

Richard M. Scanlan, MD, FCAP has no relevant financial relationships to report.

Gaurav Sharma, MD, FCAP has no relevant financial relationships to report.

Michael L. Talbert, MD, FCAP has no relevant financial relationships to report.

Christina M. Wojewoda, MD, FCAP has no relevant financial relationships to report.


• Prepare for an inspection prior to conducting the inspection.

• Perform an inspection using the CAP resources.

• Determine what constitutes compliance with the CAP accreditation requirements.

• Apply the key requirements from All Common, Laboratory General, and discipline-specific CAP checklists.

• Identify deficiencies and recommendations and appropriately document findings.


CME Category 1: The CAP designates this live educational activity for a maximum of 5.50 AMA PRA Category 1


4

Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CE (Continuing Education for non-physicians): 5.50 A1998C Quality Improvement and Validation Solutions for Every Laboratory’s Operations

Susan A. Fuhrman, MD, FCAP has no relevant financial relationships to report.

Jeffrey D. Goldsmith, MD, FCAP has no relevant financial relationships to report.

Eric D. Hsi, MD, FCAP has no relevant financial relationships to report.


Anthony A. Killeen, MD, PhD, FCAP has the following relevant financial relationships to report: Diasorin, ivestigator, employer receives grant funds; ARKRAY, investigator, employer receives grant funds.

Raouf E. Nakhleh, MD, FCAP (Moderator) has no relevant financial relationships to report.

James H. Nichols, PhD, DABCC has no relevant financial relationships to report.



• Identify new and emerging topics within the various disciplines.

• Exchange information and share solutions with experts and peers to identify solutions to common problems.

• Identify challenges to method performance using real-world examples.

• Apply evidence-based guidelines to ensure each immunohistochemistry assay is validated prior to reporting on patient samples.

• Explain possible differences in immunohistochemistry validation requirements based on variations in fixative or specimen type.



CE (Continuing Education for non-physicians): 5.75 H1615S Peripheral Blood Lymphoproliferative Disorders: Leukemias, Lymphomas, and Reactive Mimickers

Kyle T. Bradley, MD, MS, FCAP has no relevant financial relationships to report.

Jerry W. Hussong, MD, DDS, FCAP has the following relevant financial relationships to report: Sonic Healthcare, employee, board member, salary, stock option.

Sherrie L. Perkins, MD, PhD, FCAP has the following relevant financial relationships to report: ARUP Laboratories, CEO, board member, salary.


• Distinguish normal/reactive lymphocytes from neoplastic lymphoid proliferations.

• Recognize the morphologic and phenotypic features of acute lymphoblastic leukemias, chronic lymphoid


5

leukemias, and peripheralized lymphomas.

• Determine how to select cases for flow cytometry and other ancillary testing based on morphologic and clinical findings.


CME Category 1: The CAP designates this live educational activity for a maximum of 3.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. H1880C From Social Media to the Water Cooler: How to Be a Better Communicator

Timothy C. Allen, MD, JD, FCAP has no relevant financial relationships to report.

Paul Bachner, MD, FCAP has no relevant financial relationships to report.

Eric F. Glassy, MD, FCAP has the following relevant financial relationships to report: Leica BioSystems, medical advisory board member, consulting fee; Liberty Health, consultant, consulting fee; Gestalt Diagnostics, medical advisory board, consuling fee.


• Identify social media applications for your practice.

• Apply better practices for meetings.

• Review good and bad uses of emails.

• Apply new techniques for written, verbal, and visual communication.



H1943S Flow Cytometry Based on the Revised WHO Classification: Key Diagnoses That You Never Want to Miss

David M. Dorfman, MD, PhD, FCAP has no relevant financial relationships to report.

William J. Karlon, MD, PhD, FCAP has the following relevant financial relationships to report: Genentech, Inc., spouse of employee, salary, stock; University of California, San Francisco, employee, salary.

Michael A. Linden, MD, PhD, FCAP has the following relevant financial relationships to report: Cell Signaling Technology, inventor, royalties; Jazz Pharmaceuticals, advisory board member, consulting fee.


• Identify flow cytometry gating strategies to avoid exclusion of neoplastic populations.

• Recognize nonneoplastic populations by flow cytometry that mimic neoplasia.

• Discover where unexpected atypical populations are most likely to be identified in standard flow cytometry screening tubes.

• Recognize flow cytometric approaches for the characterization of new and provisional diagnostic entities included in the newly revised WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues.


CME Category 1: The CAP designates this live educational activity for a maximum of 3.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate


6

with the extent of their participation in the activity. M1710S Problems and Controversies in the Interpretation of Thyroid Nodules

Saul Suster, MD, FCAP has no relevant financial relationships to report.


• Interpret the criteria for separating benign from malignant follicular nodules of the thyroid.

• Identify the role of immunohistochemistry and molecular pathology in the diagnosis.

• Explain the new nomenclature noninvasive tumors with papillary features.


CME Category 1: The CAP designates this live educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. M1722C Hot Topics in Hemostasis: Hemostasis Testing for New Hemophilia Drugs, Age-Adjusted D-dimer, and Limitations of Point-of-Care INR

Russell A. Higgins, MD, FCAP has the following relevant financial relationships to report: Stago, consultant, consulting fee.

Karen A. Moser, MD, FCAP has no relevant financial relationships to report.


• Assess the performance of your factor assays in the presence of new extended half-life FVIII and FIX replacement products.

• Identify appropriate hemostasis tests for patients receiving emicizumab therapy.

• Discuss the risks and benefits of implementing age-specific D-dimer cutoff values.

• Identify the limitations of point-of-care prothrombin time (PT)/international normalize ratio (INR) testing and develop protocols to limit risk.


CME Category 1: The CAP designates this live educational activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. M1741S Validating a Whole Slide Imaging System—A Case-Based Approach to the CAP Guidelines

Brent T. Tan, MD, PhD, FCAP has no relevant financial relationships to report.


• Design a validation study for a whole slide imaging system that meets the CAP guidelines.

• Determine the human resources required for a validation study.

• Calculate the concordance rate between standard microscopy of glass slides versus whole slide scanned images.

• Determine when a whole slide imaging system needs to be revalidated.


CME Category 1: The CAP designates this live educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should


7

only claim credit commensurate with the extent of their participation in the activity.

CE (Continuing Education for non-physicians): 1.25 M1821S The Real-Time Anatomic Pathology Diagnostic Management Team Conference

Timothy C. Allen, MD, JD, FCAP has no relevant financial relationships to report.

Harpreet K. Talwar, MD has no relevant financial relationships to report.


• Recognize the importance of the real-time anatomic pathology diagnostic management team conference and the extent to which it will benefit patients and pathologists.

• Describe the specific technical requirements of a successful conference.

• Differentiate the roles of the conference participants.

• Identify the proscribed role of the pathologist as a member of the patient's care team consulting with the patient via the conference.


CME Category 1: The CAP designates this live educational activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. M1824S The Challenge of Laboratory-Developed Tests: A Regulatory and Legislative Update

Jonathan R. Genzen, MD, PhD, FCAP has no relevant financial relationships to report.


• Identify regulatory authority for reagents under the Medical Device Amendments.

• Recognize requirements for assay validations under the Clinical Laboratory Improvement Amendments of 1988.

• Appraise current regulatory efforts regarding laboratory-developed tests (LDTs) at the federal level.

• Assess the costs and benefits of LDT regulatory oversight in their professional practice.


CME Category 1: The CAP designates this live educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. M1872S Papillary Lesions of the Breast

Xiaoxian (Bill) Li, MD, PhD, FCAP has no relevant financial relationships to report.


• Diagnose the papillary lesions of the breast by morphology and appropriate ancillary studies.

• Identify the current treatment options and prognosis of the papillary lesions of the breast.




8

with the extent of their participation in the activity. M1876S Case-Based Identification of Parasites in Tissues and Cytologic Specimens

Julie A. Ribes, MD, PhD, FCAP has no relevant financial relationships to report.


• Identify structures in tissues that indicate possible parasites.

• Delineate parasite-tissue tropisms.

• Generate a parasite differential diangosis based on the tissue/specimen source, stage of life cycle involved, or inflammatory cell response.


CME Category 1: The CAP designates this live educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. M1903C CAR-T Therapy: What Does it Mean for Pathologists?

Allison M. Cushman-Vokoun, MD, PhD, FCAP has no relevant financial relationships to report.

Sophia Yohe, MD, FCAP has no relevant financial relationships to report.


• Explain the science behind the development of chimeric antigen receptor T-cells (CAR-T) cells and the clinical utility of CAR-T in hematopoietic malignancies.

• List three possible adverse effects of CAR-T therapy administration

• Discuss regulatory and reimbursement issues associated with CAR-T therapy.

• Recognize the future potential in CAR-T therapy in various cancers.


CME Category 1: The CAP designates this live educational activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. M1904C Physician Resilience and Wellness: The Path to Workplace Autonomy

Robert L. Breckenridge, MD, MBA, FCAP has no relevant financial relationships to report.

Erin Rubin, MD, FCAP has no relevant financial relationships to report.


• Apply tools and best practices to empower pathology practice autonomy.


CME Category 1: The CAP designates this live educational activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. M1916C Small Specimens Great Outcomes: New CAP Guideline on Collection and Handling of Thoracic Small Biopsy and Cytology Specimens for Ancillary Studies

Sinchita Roy-Chowdhuri, MD, PhD, FCAP has no relevant financial relationships to report.


• Appraise various sampling techniques to optimize diagnostic yield.


9

• Apply evidence-based recommendations to optimize the collection and handling of thoracic small biopsy and cytology specimens for ancillary testing.

• Assess the changes needed to comply with the guideline recommendations.



M1930C Dysplasia in Barrett’s Esophagus: Can We Ever Agree?

Rish K. Pai, MD, PhD has no relevant financial relationships to report.

Marcela A. Salomao, MD, FCAP has no relevant financial relationships to report.


• Describe the pathologic criteria that define dysplasia in Barrett's esophagus.

• Examine the distinguishing features that differentiate Barrett’s esophagus from reactive processes.

• Recognize the pathologic, clinical, and endoscopic factors that guide therapy in Barrett's esophagus-associated dysplasia and carcinoma.

• Summarize the features used to stage and report resected esophageal adenocarcinoma, including the evaluation of tumors treated with neoadjuvant therapy.


CME Category 1: The CAP designates this live educational activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit

commensurate with the extent of their participation in the activity. M1944S Molecular Genomic Oncology for the Practicing Surgical Pathologist

C. Leilani Valdes, MD, FCAP has no relevant financial relationships to report.

Sophia L. Yohe, MD, FCAP has no relevant financial relationships to report.


• Advise clinicians about the best test to order.

• Select the best specimen for testing.

• Recommend specific genomic testing for common solid tumors.

• Discuss the significance of variants of undetermined significance with clinicians.


CME Category 1: The CAP designates this live educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. M1947C Diagnosing Hepatocellular Neoplasms in Tiny Specimens: What the LF@BP!

Marcela A. Salomao, MD, FCAP has no relevant financial relationships to report.


• Identify well-differentiated hepatocellular lesions, even in small biopsy specimens.

• Tailor optimized immunohistochemical panels that can be used in the


10

evaluation of small liver biopsy specimens.

• Describe the most common metastatic lesions that mimic hepatocellular tumors and summarize the key features used to distinguish these entities.


CME Category 1: The CAP designates this live educational activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. M1952C Molecular Oncology Tumor Board: Carcinoma of Unknown Primary

Alexander Drilon, MD has the following relevant financial relationships to report: Ignyta / Roche / Genentech, advisory board, honoraria; Loxo / Bayer / Lilly, advisory board, honoraria; TP Therapeutics, advisory board, honoraria; AstraZeneca, advisory board, honoraria; Pfizer, advisory board, honoraria; Blueprint, advisory board, honoraria; Takeda / Ariad / Millenium, advisory board, honoraria; Helsinn, advisory board, honoraria; Beigene, advisory board, honoraria; BergenBio / Hengrui / Exelixis / Bayer / Tyra / Verastem / MORE Health / Exelixis / Teva / Taiho / PharmaMar / Foundation / WoltersKluwer / Merck / Puma, advisory board, honoraria.

Rondell P. Graham, MBBS, FCAP has no relevant financial relationships to report.


• Explain key concepts in tumor genomics in carcinoma of unknown primary.

• Discuss the interpretation of results from molecular tumor profiles, including the identification of actionable aberrations.

• Examine how tumor profiling data may be utilized to direct care and

treatment strategies when applied to patient cases.


CME Category 1: The CAP designates this live educational activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. M1966C Demystifying Key Concepts in Value-Based Health Care: A Simplified Guide for the Pathologist and Laboratory Medical Director

Tarush Kothari, MD, MPH, FCAP has no relevant financial relationships to report.



• Identify key concepts in hospital value-based payment and delivery programs required by the Centers for Medicare & Medicaid Services (CMS).

• Explain the terminology, structure, and interplay between different value-based health care programs.

• Translate concepts of value-based care delivery and payment programs to drive changes in laboratory operations and quality management.




11

with the extent of their participation in the activity. M1971S How is My Payment Determined for Pathology Services?

Jonathan L. Myles, MD, FCAP has no relevant financial relationships to report.

Mark S. Synovec, MD, FCAP has no relevant financial relationships to report.


• Explain CPT, AMA/Specialty Society Relative Value Scale Update Committee (RUC), resource-based relative value scale (RBRVS), relative value units (RVUs), and PFS.

• Describe how a new code is initiated, developed, valued, and put into practice.

• Describe how existing codes are modified.

• Distinguish between the Medicare PFS valuation and Medicare Clinical Laboratory Fee Schedule (CLFS).


CME Category 1: The CAP designates this live educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. M1978C Transfusion Transmitted Disease, What to Do: Zika Virus and Babesia

Susan L. Stramer, MS, PhD has no relevant financial relationships to report.


• Recognize the need for the introduction of an intervention to support blood recipient safety.

• Recognize the background and epidemiology of vector-borne

agents, particularly Zika virus and Babesia microti.

• Define interventions for these agents and their effectiveness.

• Recognize patients who may be infected with these agents as a result of transfusion.


CME Category 1: The CAP designates this live educational activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. M1979C Vascular Changes in Lung Biopsies: When and What to Report

Frank Schneider, MD, FCAP has no relevant financial relationships to report.

Kristen L. Veraldi, MD, PhD has no relevant financial relationships to report.


• Recognize pulmonary capillaritis and vasculitis.

• Decide which vascular abnormalities are significant enough to report.

• Incorporate hemodynamic and serologic tests results.

• Assess vascular changes in a background of underlying lung diseases.

• Appreciate the clinical workup and management of pulmonary vascular disease.


CME Category 1: The CAP designates this live educational activity for a maximum of 1.00 AMA PRA Category 1


12

Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. M1991C Root Causes Analysis: From Blame to Gain

Rich Becker, MSEd, CQIA has no relevant financial relationships to report.

Frank Schneider, MD, FCAP has no relevant financial relationships to report.


• Recognize how consistent use of root cause analysis (RCA) improves the quality culture of a laboratory.

• Recognize key steps in an RCA and corrective action methodology that meets the requirements of international quality standards such as ISO 15189.

• Recognize pitfalls in carrying out RCA.

• Recognize tools available through the CAP to assist with conducting RCA.



CE (Continuing Education for non-physicians): 1.00 P1901C Patient Microbiome

Colleen S. Kraft, MD, MS has the following relevant financial relationships to report: Rebiotix, scientific advisory board, consulting fee; Bio-Rad Laboratories, scientific advisory board, consulting fee.

Christoph A. Thaiss, PhD has no relevant financial relationships to report.

James Versalovic, MD, PhD, FCAP has the following relevant financial relationships to report: Plexus Worldwide, scientific advisory board member, consulting fee; Biogaia AB, researcher - donation (no contract), unrestricted research support; Biomica Scientific, advisory board member, stock; Seed, scientific advisory board member, stock.


• Describe the biological significance of the human microbiome.

• Discuss variability factors that affect health and disease susceptibility.

• Review present and near-future clinical applications of microbiome science in infectious and non-infectious diseases.


CME Category 1: The CAP designates this live educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. P1999C The Evolution of Molecular Diagnostics: From the Southern Blot to Extreme PCR

Carl T. Wittwer, MD, PhD, FCAP has the following relevant financial relationships to report: ARUP, medical director/consultant, salary; University of Utah, professor/inventor, royalties derived from licensing (BioFire); Clinical Chemistry (AACC), associate editor, consulting fee.


13


• Describe necessary conditions to increase the speed of polymerase chain reaction (PCR).

• Value simplicity over complexity in developing molecular techniques.

• Recognize that faster PCR and faster melting can result in better PCR and better melting.

• Summarize the evolution of molecular diagnostics.



CE (Continuing Education for non-physicians): 1.00 R1737C Managing the People Who Manage Your Information System

John H. Sinard, MD, PhD, FCAP has no relevant financial relationships to report.


• Exchange information and share solutions in a relaxed setting with your peers. Learn to improve your ability to identify solutions to common problems through interactive sessions.



CE (Continuing Education for non-physicians): 1.00

R1931C Recent Advances in the Flow Cytometric Analysis of Hematopoietic Neoplasms

David M. Dorfman, MD, PhD, FCAP has no relevant financial relationships to report.





CE (Continuing Education for non-physicians): 1.0 R1932C Standardizing the Clinical Pathology Residency Training Curriculum

Diana S. Desai, MD, FCAP has no relevant financial relationships to report.






14

with the extent of their participation in the activity.

CE (Continuing Education for non-physicians): 1.00 R1933C Demystifying Key Concepts in Value-Based Health Care: Opportunities and Challenges for Pathologists

Tarush Kothari, MD, MPH, FCAP has no relevant financial relationships to report.






CE (Continuing Education for non-physicians): 1.00 R1934C Molecular Diagnostics in Cytopathology

Sinchita Roy-Chowdhuri, MD, PhD, FCAP has no relevant financial relationships to report.




CME Category 1: The CAP designates this live educational

activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CE (Continuing Education for non-physicians): 1.00 R1935C Capillary Glucose Sampling in Critically Ill Patients: What do We Really Know?






CE (Continuing Education for non-physicians): 1.00 S1706S The Laboratory’s Role in Monitoring Chronic Opioid Therapy

Tai C. Kwong, PhD, D(ABCC) has the following relevant financial relationships to report: Roche Diagnostics, consultant, consulting fee.


• Identify the clinical issues related to opioid prescribing for chronic pain indications.


15

• Define the clinical needs and expectations of urine drug testing in pain management.

• Address preanalytic and analytic issues of drug testing for pain management.

• Interpret drug testing results.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1708C Problem Cases in Surgical Pathology: Slide Seminar

Ira J. Bleiweiss, MD has no relevant financial relationships to report.

Saul Suster, MD, FCAP has no relevant financial relationships to report.

Paul E. Wakely Jr., MD has no relevant financial relationships to report.

Bruce M. Wenig, MD, FCAP has no relevant financial relationships to report.


• Identify new entities in surgical pathology.

• Recognize common pitfalls involved in the diagnosis of uncommon tumors.

• Identify the role and limitations of special techniques for the diagnosis of uncommon tumors.



S1718C Contemporary Methods in Monoclonal Gammopathy Detection and IMWG Guidelines

David F. Keren, MD, FCAP has the following relevant financial relationships to report: InheRET, Inc., CEO, stock.


• Incorporate new International Myeloma Working Group (IMWG) guidelines into your laboratory practice.

• Implement a triage for detection of M-proteins appropriate for their clinical situation.

• Identify when to use serum-free light chain and combined heavy-light chain analyses in appropriate situations.

• Measure and characterize M-proteins by both gel and capillary electrophoresis.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1719C The WHO and Beyond: Myeloproliferative Neoplasms

Rashmi Goswami, MD, PhD has no relevant financial relationships to report.

Kristin E. Hunt Karner, MD, FCAP has no relevant financial relationships to report.


• Define the changes in the diagnostic criteria of myeloproliferative neoplasms (MPNs) in the new World


16

Health Organization (WHO) classification.

• Apply the WHO criteria to several real-life cases

• Specify best practices when using algorithm versus panel testing.

• Integrate new knowledge of additional mutations into daily practice.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1725S Method Validation and Verification: Case Studies and Laboratory Challenges

James H. Nichols, PhD, D(ABCC) has no relevant financial relationships to report.

Lauren N. Pearson, DO, MPH, FCAP has no relevant financial relationships to report.


• Identify the difference between method validation and method verification.

• Describe the studies required to document method performance.

• Interpret method performance data and statistical study outcomes.

• Identify challenges to method performance using real-world examples.



S1727S Beyond Elevated Liver Enzymes: Recognizing Patterns of Liver Injury

Safia N. Salaria, MD, FCAP has no relevant financial relationships to report.

Mary K. Washington, MD, PhD, FCAP has no relevant financial relationships to report.


• Identify patterns of liver injury caused by biliary disease, autoimmune disease, and chronic hepatitis.

• Diagnose and differentiate cirrhosis from hepatoportal sclerosis.

• Recognize drug reaction (ie, cholestasis, bile duct injury).

• Integrate laboratory values and pathologic features to formulate a cohesive diagnosis.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1729S A Practical Approach to Diagnosing Common Informatics Problems: What Every Pathologist Needs to Know

Alexis B. Carter, MD, FCAP has the following relevant financial relationships to report: American Medical Informatics Association, speaker, travel expenses and honararia.

John H. Sinard, MD, PhD, FCAP has no relevant financial relationships to report.


17

Myra L. Wilkerson, MD has no relevant financial relationships to report.


• Participate in the diagnosis of common informatics-related problems that occur in the laboratory.

• Communicate and work with local information management resources toward problem resolution.

• Identify the critical role that pathologists can/should play in the overall management strategy of laboratory data for patient care.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1739S What’s Trending? Instructive Breast Pathology Cases to Better Equip You and Your Laboratory for the Rapidly Changing Clinical and Molecular Landscape of Breast Cancer

Timothy M. D’Alfonso, MD has no relevant financial relationships to report.

Sandra J. Shin, MD, FCAP has no relevant financial relationships to report.

Sonal Varma, MD, FCAP has no relevant financial relationships to report.


• Examine the post-neoadjuvant chemotherapy-treated breast specimen in a standardized manner.

• Report the findings of the post-neoadjuvant chemotherapy-treated breast specimen.

• Classify high-risk lesions in core needle biopsy samples.

• Recognize the clinical ramifications of the diagnoses of high-risk lesions in core needle biopsy samples.

• Integrate molecular prognostic assays into the laboratory workflow.

• Communicate the findings of high-risk lesions in core needle biopsy samples to clinicians.

• Communicate information about molecular prognostic assays to clinicians.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1748S Welcome to the REAL World: Crucial Survival Tips for the New Medical Director




• List regulatory issues that can adversely impact the laboratory.

• Explain how the laboratory can optimize proficiency testing processes (eg, ordering, performance, reporting results, and investigation/response) to avoid accidental regulatory/compliance penalties.

• Describe regulatory/compliance issues that recent graduates are not


18

prepared to handle as a new laboratory director.

• Define new regulatory/compliance trends or issues of which even experienced laboratory directors may not be aware.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1792S PD-L1 Biomarker Testing: An Update for Practicing Pathologists

Georgios Deftereos, MD, FCAP has no relevant financial relationships to report.

Larissa V. Furtado, MD, FCAP has no relevant financial relationships to report.


• Identify the different PD-L1 immunohistochemistry assays that have been approved as companion diagnostic tests for PD-1/PD-L1 checkpoint inhibitors.

• Recognize the indications, specimen requirements, applications, limitations, and intricacies of

• PD-L1 immunohistochemistry testing in solid tumors with emphasis on non-small-cell lung cancer, melanoma, and gastric and gastroesophageal carcinomas.

• Recognize the different aspects of PD-L1 immunohistochemistry test development, validation, implementation, and quality control/assurance.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.50 AMA PRA Category 1 Credit(s)™.

Physicians should only claim credit commensurate with the extent of their participation in the activity. S1823S Generational Differences and Diversity: The Impact on Your Practice

Lydia P. Howell, MD, FCAP has no relevant financial relationships to report.

Amyn M. Rojiani, MD, PhD, FCAP has no relevant financial relationships to report.


• Define the generations and their needs and challenges.

• Predict future issues/needs of medical faculty using a generational perspective.

• Define diversity issues such as microaggressions and their impact in the workplace.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1828S What Lab Medical Directors Need to Know: New External Programs for Laboratory Quality Assurance

Keri J. Donaldson, MD, FCAP has no relevant financial relationships to report.

Charles S. Eby, MD, PhD, FCAP has the following relevant financial relationships to report: Bayer Pharmaceutical Company, expert witness, consulting fee; Instrumentation Laboratory, scientific advisory committee, consulting fee; Siemens Healthcare Diagnostics,


19

contracted instrument and reagent evaluations, Contracted services between my employer, Washington University in St. Louis, and Siemens. I did not recieve any direct compensation.; Instrumentation Laboratory; contracted evaluation of instruments and reagents, no direct compensation.

Anthony A. Killeen, MD, PhD, FCAP has the following relevant financial relationships to report: Diasorin, ivestigator, employer receives grant funds; ARKRAY, investigator, employer receives grant funds.


• Identify the new CAP and Centers for Medicare & Medicaid Services (CMS) requirements for quality assessment.

• Describe the importance of commutable proficiency testing (PT) samples.

• Explain the importance of multiple instrument comparisons.

• Apply ambulatory medical record validation and linearity to coagulation testing.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1836S Top 10 Diagnostic Challenges in Non-Thyroidal Head and Neck FNA Biopsy

Paul E. Wakely Jr., MD has no relevant financial relationships to report.


• Recognize major diagnostic challenges in non-thyroidal head and neck fine-needle aspiration (FNA) cytology.

• Develop practical strategies to avoid diagnostic pitfalls.

• Determine when to make a definitive diagnosis and when to give a diagnostic category to guide clinical management.

• Update the new knowledge and effectively incorporate ancillary techniques to aid diagnosis.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1842S Optimizing Rapid Onsite Evaluation in the Bronchoscopy Suite: The Basics and Beyond

Christine N. Booth, MD, FCAP has no relevant financial relationships to report.

Deborah J. Chute, MD has no relevant financial relationships to report.


• Interpret modified Giemsa-stained endoscopic transbronchial ultrasound-guided fine-needle aspiration (EBUS-FNA) cytology slides.

• Identify situations in which specimen triage is critical during EBUS-FNA rapid onsite evaluations.

• Recognize appropriate triage options that can be used during EBUS-FNA rapid onsite evaluations.

• Identify and avoid potential pitfalls in the interpretation of EBUS-FNA rapid onsite evaluations.


20


CME Category 1: The CAP designates this live educational activity for a maximum of 2.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1851S New Classifications for Cytology: Paris System for Urinary and Milan System for Salivary Gland

Jeffrey F. Krane, MD, PhD, FCAP has no relevant financial relationships to report.

Eva M. Wojcik, MD, FCAP has no relevant financial relationships to report.


• Review the basis for the Paris and Milan classification systems.

• Identify the morphological criteria and pitfalls for various benign and neoplastic entities.

• Demonstrate the role of ancillary immunocytochemical and molecular tests in lesions of these sites.

• Recognize the management options of lesions in these sites.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1854S The Interface of Cytology and Histology in Thyroid and Salivary Gland Pathology

Tarik M. Elsheikh, MD, FCAP has no relevant financial relationships to report.



• Distinguish histologically between noninvasive follicular thyroid neoplasm (NIFTP) and other follicular-patterned thyroid neoplasms.

• Utilize strict cytologic criteria in the differential diagnosis of thyroid indeterminate lesions.

• Identify the benefits and limitations of molecular studies.

• Explain updates on the Bethesda System for reporting thyroid cytopathology.

• Utilize a practical approach to evaluating salivary gland cytologic specimens, and how to best avoid potential pitfalls.

• Describe the new Milan System for reporting salivary gland cytopathology.

• Utilize a combination of histologic features and immunohistochemistry to subclassify challenging salivary gland neoplasms, and appropriately grade them when applicable.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1857S Forget Your Unease With Interstitial Lung Disease: Top 10 Pearls to Change Your Practice Immediately

Brandon T. Larsen, MD, PhD, FCAP has no relevant financial relationships to report.


21

Maxwell L. Smith, MD, FCAP has no relevant financial relationships to report.


• Integrate clinical and radiographic information into your interpretation of interstitial lung disease (ILD).

• Correctly interpret fibrotic lung disease.

• Recognize and report biopsies with acute lung injury.

• Avoid pitfalls in the assessment of granulomatous lung disease.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1858S Panreactivity in Blood Bank Testing: Causes, Serological Techniques, and Patient Care

Julie Katz Karp, MD, FCAP has no relevant financial relationships to report.

Glenn E. Ramsey, MD, FCAP has the following relevant financial relationships to report: Immucor, Inc., speaker, honararia.

Nicole D. Zantek, MD, PhD, FCAP has the following relevant financial relationships to report: Boston Scientific, employee (spouse), salary, stock; ENDO International PLC, spouse, stock; Stago Diagnostics, speaker, honoraria; Octapharma, research, research fee.


• Describe the varying causes of panreactivity in pretransfusion testing.

• Identify serological techniques that assist in determining the cause of panreactivity and identifying underlying red blood cell alloantibodies.

• Discuss how to select red blood cell units for patients with panreactivity.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1860S Uterine, Ovarian, and Tubal Serous Carcinoma in the Female Genital Tract: Differential Diagnosis and Grading

Ann Folkins, MD has no relevant financial relationships to report.

Teri A. Longacre, MD, FCAP has no relevant financial relationships to report.


• Identify differences in surgical and medical treatment of serous neoplasia subtypes.

• Utilize standard criteria to diagnose the main subtypes of serous neoplasia in the ovary/tube/peritoneum.

• Utilize p53 ancillary studies to refine classification of serous tumors.




22

S1864S How to Practically Approach Atypical Melanocytic Neoplasms (Gray-Zone Lesions) in Children and Adults

Phyu P. Aung, MD, PhD, FCAP has no relevant financial relationships to report.

Doina Ivan, MD, FCAP has no relevant financial relationships to report.


• Identify the key clinicohistopathological features leading to correct diagnosis of malignant versus benign melanocytic lesions.

• Interpret the results of ancillary studies, including molecular assays in the context of clinical and histopathologic features of each patient.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1868S Cervical Adenocarcinoma: From AGUS to Zebras—Cytology and Histology of Usual Type Adenocarcinomas and Special Variants

Christina S. Kong, MD, FCAP has no relevant financial relationships to report.

Teri A. Longacre, MD, FCAP has no relevant financial relationships to report.


• Cite specific criteria for distinguishing reactive changes from atypical glandular cells (Pap) and adenocarcinoma in situ (biopsy).

• Apply a standardized approach for integrating cervical cytology

findings with histology findings in the cervical biopsy report.

• Recognize when and how to apply the Silva classification system to invasive adenocarcinomas.

• Distinguish usual type endocervical adenocarcinomas from special variants, such as gastric type.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1869S Soft Tissue Pathology Is Fun…Really! A Crash Course for General Pathologists

Jerad M. Gardner, MD, FCAP has the following relevant financial relationships to report: JNJ, previous stock holder (retirement accounts), stock; GSK, previous stock holder (retirement accounts), stock.

Nicole D. Riddle, MD, FCAP has no relevant financial relationships to report.


• Diagnose the most common soft tissue lesions.

• Recognize common pitfalls and benign mimickers.

• Utilize appropriate ancillary tests.

• Discuss cases more clearly and confidently with clinicians.



23

CME Category 1: The CAP designates this live educational activity for a maximum of 2.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1870S Masqueraders of Malignancy in Breast Pathology: Strategies and Solutions

Yunn-Yi Chen, MD, PhD, FCAP has no relevant financial relationships to report.

Timothy W. Jacobs, MD, FCAP has no relevant financial relationships to report.


• Use a diagnostic approach to recognize and distinguish benign lesions from malignant mimickers in breast pathology.

• Effectively integrate immunohistochemistry and molecular testing into diagnostic algorithms in breast pathology.

• Identify the strengths and limitations of ancillary tests pertaining to breast pathology.

• Avoid errors and pitfalls in diagnosis of problematic and challenging breast lesions.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1877S Changing the Platelet Paradigm: How Mitigation of Bacterial Sepsis Will Change Your World

Julie L. Cruz, MD, FCAP has no relevant financial relationships to report.

Julie Katz Karp, MD, FCAP has no relevant financial relationships to report.

Susan N. Rossmann, MD, PhD, FCAP has no relevant financial relationships to report.


• Identify the risk of bacterial contamination of platelets and septic platelet transfusions.

• Define the current regulatory environment related to mitigating septic platelet transfusions, including the Food & Drug Administration (FDA) guidance Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance

• Describe the options for methods that meet the regulatory requirements for mitigating septic platelet transfusions.

• Assess the impact of mitigation methods on workflow, information systems, blood supplier relationships, product availability, and budget.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1884S Common Errors in Diagnosing Chronic Colitis and the Challenges of IBD-Associated Dysplasia

Amitabh Srivastava, MD, MBBS, FCAP has no relevant financial relationships to report.


24


• Identify key features of chronic colitis.

• Recognize the importance of using standardized nomenclature in reporting.

• Recognize the most commonly misdiagnosed mimickers of inflammatory bowel disease (IBD).

• Diagnose dysplasia and recognize the clinical implications of the diagnosis in IBD.

• Describe the role of ancillary stains in diagnosis of IBD dysplasia.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1909C Breast Cancer Biomarkers With a Focus on Quantitative Image Analysis

Zaibo Li, MD, PhD, MBA, FCAP has no relevant financial relationships to report.

Anil V. Parwani, MD, PhD, MBA, FCAP has no relevant financial relationships to report.


• Identify current breast cancer biomarkers for prognostic and therapeutic information.

• Translate the prognostic and therapeutic information into clinical practice.

• Identify and implement the Food & Drug Administration (FDA)-approved breast cancer biomarker tests in routine clinical practice.

• Implement quantitative image analysis tools for breast cancer biomarkers (HER2, ER/PR, and PD-L1) in routine clinical practice.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1914C Cytologic Atypia? Think Again! Using Updated Cytology Terminology to Minimize Cytologic Atypia and Improve Patient Management

Nirag C. Jhala, MD, FCAP has no relevant financial relationships to report.

Esther D. Rossi, MD, PhD has no relevant financial relationships to report.


• Incorporate information from the Milan System for Reporting Salivary Gland Cytopathology to distinguish between atypia and lesions with undetermined malignant potential.

• Clarify the clinical ramifications of reporting atypia of undetermined significance and follicular neoplasm in the Bethesda System for Reporting Thyroid Cytopathology in the assessment of gray-zone lesions on fine-needle aspiration (FNA) samples.

• Determine appropriate terminology for pancreatic atypia.

• Identify approaches to minimize atypical interpretations in pancreatic FNA.



25

CME Category 1: The CAP designates this live educational activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1917S Update on CAP Protocol and AJCC-TNM (8th Edition) Staging Parameters of Cutaneous Malignant Neoplasms

Phyu P. Aung, MD, PhD, FCAP has no relevant financial relationships to report.

Victor G. Prieto, MD, PhD, FCAP has the following relevant financial relationships to report: Myriad MyPath, consultant, travel expenses.


• Identify the key different clinic-histologic features in current staging criteria based on the American Joint Committee on Cancer (AJCC) 8th edition/updated CAP protocols to define the best practical approach for management of patients with cutaneous malignant neoplasms.

• Interpret and report on these clinically significant parameters and therapeutic biomarkers.

• Determine when to use ancillary studies.

• Interpret the results of ancillary studies in the context of clinical and histopathologic features of each patient.



S1921C Small Bites and Small Sites: Big Gastrointestinal Pathology Diagnostic Problems

Christina A. Arnold, MD has no relevant financial relationships to report.

Wei Chen, MD, PhD, FCAP has no relevant financial relationships to report.

Joseph Misdraji, MD has no relevant financial relationships to report.


• Recognize the changes to the nomenclature and staging of appendiceal neoplasms.

• Distinguish mucin “carry-over” from true extra-appendiceal mucin, and realize that this distinction is critical for accurate staging.

• Apply the latest guidelines to accurately diagnosis anal squamous dysplasia.

• Classify epithelial atypia in small ampullary biopsies in the setting of ulcer, strictures, and stents.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1922S Stains, Deposits, and Buds: Update on Prognostic Factors in Colorectal Carcinoma

Heather Dawson, MD has no relevant financial relationships to report.


26

Jennifer J. Findeis-Hosey, MD, FCAP has no relevant financial relationships to report.

Raul S. Gonzalez, MD, FCAP has no relevant financial relationships to report.


• Appropriately interpret MMR, HER2, and PD-L1 immunohistochemical staining of colorectal carcinomas.

• Properly stage colorectal carcinomas based on the number of tumor deposits and positive lymph nodes.

• Assess and report tumor budding.

• Identify how to deal with challenging cases of tumor budding.

• Expertly discuss the prognostic factors with surgeons and oncologists in order to ensure proper care for patients.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1924S Intraoperative Assessment of Pelvic Lesions in Female Patients: An Interactive Approach Using Cytology and Frozen Section Slides

Andres A. Roma, MD has no relevant financial relationships to report.


• Formulate a differential diagnosis based on gross lesion features, patient age, and laterality.

• Perform a diagnosis and differential diagnosis after evaluation of specimen, cytology, and frozen section slides, including pertinent clinical history.

• Communicate findings to clinician/oncologic surgeon, even when a definitive diagnosis cannot be made.

• Correlate cytology smears and frozen section slides to aid in the intraoperative assessment of pelvic lesions.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1926S New Things in the WHO Tumours of the Urinary System and Male Genital Organs Blue Book and 8th Edition of AJCC Staging That Every Pathologist Should Know

Rajal B. Shah, MD, FCAP has no relevant financial relationships to report.

Ming Zhou, MD, PhD, FCAP has no relevant financial relationships to report.


• Diagnose and classify new genitourinary (GU) tumors.

• Apply new and modified grading criteria for GU tumors.

• Apply new TNM staging criteria for GU tumors.

• Report GU cancers using the CAP cancer protocols.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should


27

only claim credit commensurate with the extent of their participation in the activity. S1940C Challenging Areas in Prostate Pathology Interpretation

Giovanna A. Giannico, MD, FCAP has no relevant financial relationships to report.

Sean R. Williamson, MD has no relevant financial relationships to report.


• Differentiate intraductal carcinoma of the prostate from other intraductal lesions.

• Apply accurate grading of coexisting tumor.

• Recognize the major morphologic variants of neuroendocrine tumors of the prostate.

• Identify deceptively bland variants of prostate adenocarcinoma.

• Utilize the most important pathologic reporting parameters for clinicians in preparing pathology reports and considering differential diagnoses.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1945C To Measure or Not to Measure: The Clinical Laboratory’s Contribution in the Setting of Direct Oral Anticoagulant (DOAC) Therapy

Karen A. Moser, MD, FCAP has no relevant financial relationships to report.

Amanda M. VanSandt, DO, FCAP has the following relevant financial relationships to report: CSL Behring, contract medical director, hourly compensation.

Oksana Volod, MD, FCAP has the following relevant financial relationships to report: STAGO, consultant, consulting fee; Haemonetics, consultant, consulting fee.


• Describe the currently available direct oral anticoagulants (DOACs) and explain their mechanism of action.

• Discuss labeling for DOAC regarding laboratory monitoring.

• Identify clinical scenarios in which measuring DOAC in the laboratory may provide actionable information.

• Consult confidently with clinical colleagues to interpret laboratory results measuring and/or affected by DOAC.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1946C Pearls and Pitfalls in the Interpretation of Endometrial Biopsies

Mamta Gupta, MD, MBBS, FCAP has no relevant financial relationships to report.

Ricardo R. Lastra, MD has no relevant financial relationships to report.


• Recognize common benign conditions often mistaken for neoplasia on endometrial biopsies.


28

• Identify differences in various classifications for endometrial precursor lesions and their clinical significance.

• Explain histologic typing and grading of endometrial carcinomas.

• Recognize unusual and rare lesions that may be diagnosed in endometrial biopsies.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1949C The Current Paradigm of Head and Neck Pathology: Integration of Traditional Light Microscopy and Novel Molecular Findings

Juan C. Hernandez-Prera, MD has no relevant financial relationships to report.



• Recognize the major changes introduced by the 2017 WHO Classification of Head and Neck Tumours derived from molecular advances.

• Identify traditional histological features that should prompt further molecular testing.

• Recognize accepted testing guidelines for viral-related head and neck cancers.

• Identify the utility of chromosomal alteration testing in salivary gland tumors.

• Integrate molecular ancillary testing in the diagnosis of head and neck tumors.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1950C Intelligence Test: Implementing, Verifying, and Monitoring the Performance of Systems Incorporating Machine Learning and Artificial Intelligence

Matthew G. Hanna, MD, FCAP has the following relevant financial relationships to report: PaigeAI, consultant, consulting fee.

James H. Harrison Jr., MD, PhD, FCAP has no relevant financial relationships to report.


• Identify the common types of performance and quality problems that can occur in machine learning systems.

• Determine whether the data used to train a machine learning model is applicable to the data available at a deployment site.

• Outline an appropriate method for validating a machine learning system using data from a deployment site.

• Describe the current status and likely future direction of regulation of machine learning systems.




29

with the extent of their participation in the activity. S1953S A Glimpse into the Future Practice: Transitioning to an Effective Pathology Practitioner in the Age of Machine Learning

Anand S. Dighe, MD, PhD has no relevant financial relationships to report.

Barbara S. Ducatman, MD, FCAP has no relevant financial relationships to report.

Michael D. Feldman, MD, PhD has the following relevant financial relationships to report: Philips Digital Pathology, consultant, consultant fee.

Andrew R. Janowczyk, PhD has no relevant financial relationships to report.


• Describe foundational information on artificial intelligence and machine learning.

• Identify practical examples of the application of these technologies to pathology.

• Appreciate how the technologies might impact the future of pathology practice.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1955C Curbside Consult in Clinical Pathology

Diana S. Desai, MD, FCAP has no relevant financial relationships to report.

Brenda J. Grossman, MD has no relevant financial relationships to report.

William E. Winter, MD, FCAP has no relevant financial relationships to report.


• Recommend optimal and safe transfusion therapy when treating patients with known or potential red blood cell antibodies.

• Recognize variables that routinely affect the interpretation of potassium results and drugs of abuse screens.

• Interpret coagulation studies performed to rule out commonly suspected hemostatic disorders.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1956C Point-of-Care Testing Pitfalls – What You Don’t Know Can Hurt You


Deborah A. Perry, MD, FCAP has no relevant financial relationships to report.


• Identify areas of risk within your institution’s point-of-care testing (POCT) program and develop a strategy to mitigate those risks.

• Identify the regulatory expectations for directors of POCT programs.


30

• Use risk analysis tools to identify error prone steps in POCT procedures.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1959S Don't Be THAT Lab

Richard M. Scanlan, MD, FCAP has no relevant financial relationships to report.

Michael L. Talbert, MD, FCAP has no relevant financial relationships to report.


• Identify situations in the laboratory which could lead to application of accreditation sanctions.

• Discuss mitigation strategies for directors to use to avoid having their laboratory sanctioned.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1961C All That You Wanted to Know But Were Afraid to Ask: Multidisciplinary Insights Into Molecular Testing in Non-Small Cell Lung Carcinoma (NSCLC)

Vijayalakshmi Ananthanarayanan, MD, MBBS, FCAP has no relevant financial relationships to report.

Lauren L. Ritterhouse, MD, PhD, FCAP has the following relevant financial relationships to report: Bristol Myers Squibb, advisor, honoraria; Loxo Oncology, advisor, honorarium.

Deepa S. Subramaniam, MD has the following relevant financial relationships to report: Astra Zeneca, advisory board member, speaker, consultant fees, honoraria; Genentech, speaker, honararia; Takeda Oncology, speaker, advisory board, consulting fee, honararia.


• Identify the clinical relevance of molecular alterations in non-small cell lung carcinoma (NSCLC).

• Recognize the scope, strengths, and limitations of the limited and extended gene panels for molecular/genomic testing.

• Evaluate the preanalytic, analytic, and postanalytic variables in molecular testing that affect efficiency and turnaround time.

• Determine the cost-effectiveness of bringing a test in house versus send outs, proficiency testing, and billing and reimbursement issues with molecular testing.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1963S Smart Test Ordering

Peter L. Perrotta, MD, FCAP has no relevant financial relationships to report.

Gary W. Procop, MD, MS, FCAP has no relevant financial relationships to report.


31

Ron B. Schifman, MD, FCAP has no relevant financial relationships to report.


• Describe effective strategies for improving the utilization of laboratory tests.

• Identify how to implement an effective test utilization management program.

• Discuss the recommendations of the 2017 Clinical and Laboratory Standards Institute (CLSI) report on test utilization.

• Partner more effectively with clinicians to improve patient diagnosis and outcomes.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1965C Fundamentals of Placenta Pathology: Keys to an Accurate Diagnosis

Michael A. Arnold, MD, PhD, FCAP has no relevant financial relationships to report.

Selene C. Koo, MD, PhD has no relevant financial relationships to report.


• Describe the gross and microscopic anatomy of the placenta, membranes, and umbilical cord using appropriate terminology.

• Distinguish between normal variants and pathologic changes in the placenta, with an emphasis on the impact on current and future pregnancies.

• Describe the normal anatomy and pathologic conditions that can be seen in twin placentas.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1967S Thriving in MIPS and Other Value-Based Payment Programs

Diana M. Cardona, MD, FCAP has no relevant financial relationships to report.

Emily E. Volk, MD, MBA, FCAP has no relevant financial relationships to report.


• Describe the financial impact of Medicare’s quality payment program on your practice.

• Identify your eligibility and participation in value-based payment programs.

• Identify ways to reduce the burden of participating in these programs, while demonstrating quality and maximizing reimbursement.

• Identify the best reporting option for your practice to demonstrate value to the appropriate stakeholder.




32

S1975C Mediastinal Lesions – Let’s Master the Challenge

Andre L. Moreira, MD, PhD, FCAP has no relevant financial relationships to report.

Anja C. Roden, MD, FCAP has no relevant financial relationships to report.


• Distinguish thymoma from lymphoma, benign thymic gland, thymic carcinoma, and thymic neuroendocrine tumor on a small biopsy.

• Demonstrate a diagnostic approach to mediastinal epithelioid and spindle cell tumors.

• Apply recent staging criteria correctly to thymic epithelial tumors.

• Accurately diagnose fibrosing mediastinal lesions.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. S1990C 2019 CAP Accreditation Checklist Updates: Changes That Matter

Harris S. Goodman, MD, FCAP has the following relevant financial relationships to report: Dignity Health, independent contractor, compensation; Alameda Health System, independent contractor, compensation.

Bharati S. Jhaveri, MD, FCAP has no relevant financial relationships to report.


• Describe key changes and the rationale for changes in the 2019 version of the CAP Accreditation Program requirements.

• Use the CAP resources to identify changes.

• Implement any necessary changes to ensure compliance with new accreditation requirements.



CE (Continuing Education for non-physicians): 2.00 V1873C Inflammatory Bowel Disease and Colon Cancer: Selected Update in Diagnosis and Staging

Amitabh Srivastava, MD, MBBS, FCAP has no relevant financial relationships to report.


• Score tumor budding in colon.

• Identify the utility, or lack thereof, of special stains in diagnosing serosal perforation or vascular invasion in colon cancer staging.

• Recognize common mimickers of inflammatory bowel disease (IBD), including checkpoint inhibitor colitis.

• Recognize common pitfalls in dysplasia diagnosis.

• Identify specific morphologic phenotypes of dysplasia in IBD and their clinical relevance.

The following In-Kind Support has been received for this activity: Nikon loan of microscopes, digital cameras and support staff. No commercial support has been received for this activity.


33

CME Category 1: The CAP designates this live educational activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. V1888C Practical Issues in Testicular Pathology: A Case-Based Discussion

Muhammad T. Idrees, MD, FCAP has no relevant financial relationships to report.

Chia-Sui Kao, MD, FCAP has no relevant financial relationships to report.


• Identify diagnostic challenges of testicular tumors and appropriately utilize immunohistochemical stains if needed.

• Classify testicular tumors utilizing the most up-to-date World Health Organization (WHO) 2016 terminology.

• Apply methods to ensure accurate staging of testicular tumors.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. V1920C Colon Polyps, From the Mundane to the Exotic: A Comprehensive Microscopy Tutorial

Lysandra Voltaggio, MD has no relevant financial relationships to report.


• Identify neoplastic and nonneoplastic colon polyps.

• Address common and recurring issues related to epithelial polyps.

• Recognize common diagnostic pitfalls.


CME Category 1: The CAP designates this live educational activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. V1987C Correlating the Sonogram With Cytology in Pathologist-Performed Ultrasound-Guided FNA

David K. W. Lieu, MD, MBA, RDMS, FCAP has no relevant financial relationships to report.


• Recognize normal and abnormal ultrasound images of the thyroid, salivary glands, lymph nodes, head and neck, and breast.

• Correlate the results of rapid onsite evaluation (ROSE) with the ultrasound images.

• Perform additional studies, if needed, based on sonographic-pathologic correlation.



34

CME Category 1: The CAP designates this live educational activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. V1989C Papillary and Spindle Cell Lesions of the Breast: A Case-Based Discussion With Emphasis in Differential Diagnosis and Pitfalls

Xiaoxian (Bill) Li, MD, PhD, FCAP has no relevant financial relationships to report.

Zaibo Li, MD, PhD, MBA, FCAP has no relevant financial relationships to report.


• Discuss the morphological features, ancillary studies, and frequently encountered problems when diagnosing papillary and spindle cell lesions of the breast.

• Explain the relevant prognosis and clinical management of these lesions to prepare pathologists to play an essential role in multidisciplinary care of breast cancer patients.

• Identify some rare and easily-misdiagnosed entities such as encapsulated papillary carcinoma, solid papillary carcinoma, fibromatosis-like metaplastic carcinoma, and spindle cell carcinoma.

• Review related benign breast lesions such as intraductal papilloma, sclerosing adenosis, fibromatosis, and collagenous spherulosis with regard to their consideration in the differential.


CME Category 1: The CAP designates this live educational

activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

College of American Pathologists 325 Waukegan Road Northfield, IL 60093

© 2019 College of American Pathologists. All rights reserved.

Documents

DISCLOSURE GUIDE - CAP Annual Meeting...Disclosure Guide cap19 4 Credit(s) .Physicians should only claim credit commensurate with the extent of their participation in the activity